Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYZINE PAMOATE versus KETOTIFEN FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYZINE PAMOATE versus KETOTIFEN FUMARATE.
HYDROXYZINE PAMOATE vs KETOTIFEN FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyzine pamoate is a piperazine derivative with antihistamine (H1 receptor antagonist) and anticholinergic properties. It also has sedative, anxiolytic, and antiemetic effects, likely mediated through suppression of subcortical regions of the central nervous system.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
Oral: 50-100 mg every 6 hours as needed for pruritus or anxiety; maximum 600 mg/day. IM: 25-100 mg every 4-6 hours as needed.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours (range 14-25 hours) in adults; may be prolonged in elderly or hepatic impairment.
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal elimination accounts for approximately 50% of metabolites.
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Category A/B
Category A/B
Antihistamine
Antihistamine / Mast Cell Stabilizer